| Cost of disorders of the brain in Europe 2010 A Gustavsson, M Svensson, F Jacobi, C Allgulander, J Alonso, E Beghi, ... European neuropsychopharmacology 21 (10), 718-779, 2011 | 1611 | 2011 |
| Resources for mental health: scarcity, inequity, and inefficiency S Saxena, G Thornicroft, M Knapp, H Whiteford The lancet 370 (9590), 878-889, 2007 | 1564 | 2007 |
| Financial cost of social exclusion: follow up study of antisocial children into adulthood S Scott, M Knapp, J Henderson, B Maughan Bmj 323 (7306), 191, 2001 | 1202 | 2001 |
| Costing psychiatric interventions J Beecham, M Knapp Measuring mental health needs 2, 200-224, 2001 | 1158 | 2001 |
| Costs of autism spectrum disorders in the United Kingdom and the United States AVS Buescher, Z Cidav, M Knapp, DS Mandell JAMA pediatrics 168 (8), 721-728, 2014 | 1106 | 2014 |
| Defeating Alzheimer's disease and other dementias: a priority for European science and society B Winblad, P Amouyel, S Andrieu, C Ballard, C Brayne, H Brodaty, ... The Lancet Neurology 15 (5), 455-532, 2016 | 1027 | 2016 |
| World Alzheimer report 2016: improving healthcare for people living with dementia: coverage, quality and costs now and in the future M Prince, A Comas-Herrera, M Knapp, M Guerchet, M Karagiannidou Alzheimer’s Disease International (ADI), 2016 | 928 | 2016 |
| The effectiveness of supported employment for people with severe mental illness: a randomised controlled trial T Burns, J Catty, T Becker, RE Drake, A Fioritti, M Knapp, C Lauber, ... The Lancet 370 (9593), 1146-1152, 2007 | 760 | 2007 |
| Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology DS Baldwin, IM Anderson, DJ Nutt, B Bandelow, A Bond, JRT Davidson, ... Journal of Psychopharmacology 19 (6), 567-596, 2005 | 686 | 2005 |
| Poverty and mental disorders: breaking the cycle in low-income and middle-income countries C Lund, M De Silva, S Plagerson, S Cooper, D Chisholm, J Das, M Knapp, ... The lancet 378 (9801), 1502-1514, 2011 | 658 | 2011 |
| Donepezil and memantine for moderate-to-severe Alzheimer's disease R Howard, R McShane, J Lindesay, C Ritchie, A Baldwin, R Barber, ... New England Journal of Medicine 366 (10), 893-903, 2012 | 656 | 2012 |
| The global costs of schizophrenia M Knapp, R Mangalore, J Simon Schizophrenia bulletin 30 (2), 279-293, 2004 | 642 | 2004 |
| Cognitive remediation therapy in schizophrenia: randomised controlled trial T Wykes, C Reeder, S Landau, B Everitt, M Knapp, A Patel, R Romeo The British journal of psychiatry 190 (5), 421-427, 2007 | 637* | 2007 |
| Effect of telehealth on use of secondary care and mortality: findings from the Whole System Demonstrator cluster randomised trial A Steventon, M Bardsley, J Billings, J Dixon, H Doll, S Hirani, M Cartwright, ... Bmj 344, 2012 | 610 | 2012 |
| Dementia UK: update M Prince, M Knapp, M Guerchet, P McCrone, M Prina, A Comas-Herrera, ... Alzheimer’s Society 1014, 43-4, 2014 | 568* | 2014 |
| Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. SC Smith, DL Lamping, S Banerjee, R Harwood, B Foley, P Smith, ... Health Technology Assessment (Winchester, England) 9 (10), 1-iv, 2005 | 546 | 2005 |
| Training carers of stroke patients: randomised controlled trial L Kalra, A Evans, I Perez, A Melbourn, A Patel, M Knapp, N Donaldson Bmj 328 (7448), 1099, 2004 | 545 | 2004 |
| Paying the price: the cost of mental health care in England to 2026 PR McCrone, S Dhanasiri, A Patel, M Knapp, S Lawton-Smith King's Fund, 2008 | 503 | 2008 |
| Dementia UK M Knapp, M Prince, E Albanese, S Banerjee, S Dhanasiri, JL Fernandez, ... London: Alzheimer’s Society 7, 2007 | 502 | 2007 |
| Long-term conditions and mental health: the cost of co-morbidities C Naylor, M Parsonage, D McDaid, M Knapp, M Fossey, A Galea The King's Fund, 2012 | 474 | 2012 |
